← Leaderboards
Robert Turner Schooley
University Of Colorado Denver
$73,100,957
Attributed
$74,992,098
Total exposure
38
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$78,280,538 · 39
By mechanism
U01$49,235,944 · 4
R01$8,842,355 · 3
P30$6,775,105 · 6
M01$5,901,277 · 21
T32$4,773,121 · 2
D43$1,514,000 · 1
Top collaborators
- Emilia Virginia Noormahomed5 shared
- Karl Y Hostetler3 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- John G. Fitz$21,349,867
- Kathryn V Holmes$8,438,832
- Aleem Siddiqui$17,154,020
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHiv InfectionsHuman SubjectAids TherapyHuman Therapy EvaluationAntiaids AgentCombination ChemotherapyProtease InhibitorHuman Immunodeficiency Virus 1Drug Screening /EvaluationZidovudineIndinavirLamivudineAntiviral AgentsDrug Administration Rate /DurationLeadStavudineBaseVirus RnaDesignNucleoside AnalogMorbidity - Disease RateCommunitiesVirus Replication
Grant awards (155)
Core I: International$343,764
P30 · FY2025 · AI · contact PI
Core I: International$176,216
P30 · FY2024 · AI · contact PI
Revising Anti-coronavirus Compounds to Enhance Activity and Optimize Delivery$750,972
R01 · FY2023 · AI · contact PI
Core I: International$198,603
P30 · FY2023 · AI · contact PI
Revising Anti-coronavirus Compounds to Enhance Activity and Optimize Delivery$751,145
R01 · FY2022 · AI · contact PI
Core I: International$182,121
P30 · FY2022 · AI · contact PI
Revising Anti-coronavirus Compounds to Enhance Activity and Optimize Delivery$766,165
R01 · FY2021 · AI · contact PI
Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles$579,659
R01 · FY2021 · AI · contact PI
Enhancing Advanced Biomedical Training in Mozambique$302,400
D43 · FY2021 · TW · contact PI
Development of Sustained-Release Anti-coronavirus Nucleoside Phosphonate compounds$169,785
R01 · FY2021 · AI · contact PI
Core I: International$132,669
P30 · FY2021 · AI · contact PI
Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles$749,444
R01 · FY2020 · AI · contact PI
Enhancing Advanced Biomedical Training in Mozambique$302,400
D43 · FY2020 · TW · contact PI
Core I: International$282,481
P30 · FY2020 · AI · contact PI
Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles$749,444
R01 · FY2019 · AI · contact PI
Enhancing Advanced Biomedical Training in Mozambique$302,400
D43 · FY2019 · TW · contact PI
Core I: International$265,802
P30 · FY2019 · AI · contact PI
Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles$792,844
R01 · FY2018 · AI · contact PI
Research in Infectious Disease$371,774
T32 · FY2018 · AI · contact PI
Enhancing Advanced Biomedical Training in Mozambique$302,400
D43 · FY2018 · TW · contact PI
Core I: International$126,077
P30 · FY2018 · AI · contact PI
Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles$749,444
R01 · FY2017 · AI · contact PI
Research in Infectious Disease$366,913
T32 · FY2017 · AI · contact PI
Enhancing Advanced Biomedical Training in Mozambique$304,400
D43 · FY2017 · TW · contact PI
Research in Infectious Disease$367,751
T32 · FY2016 · AI · contact PI
Research in Infectious Diseases$295,083
T32 · FY2014 · AI · contact PI
Orally Active Nucleoside Phosphonates for Hepatitis C Virus$499,920
R01 · FY2013 · AI · contact PI
Research in Infectious Diseases$411,841
T32 · FY2013 · AI · contact PI
Orally Active Nucleoside Phosphonates for Hepatitis C Virus$545,533
R01 · FY2012 · AI · contact PI
Research in Infectious Diseases$407,868
T32 · FY2012 · AI · contact PI
International Program$179,874
P30 · FY2012 · AI · contact PI
Multiplex Nucleic Acid Detection Devices for the Diagnosis of Respiratory Viruses$795,579
U01 · FY2011 · AI · contact PI
Orally Active Nucleoside Phosphonates for Hepatitis C Virus$587,665
R01 · FY2011 · AI · contact PI
Research in Infectious Diseases$392,255
T32 · FY2011 · AI · contact PI
International Program$263,506
P30 · FY2011 · AI · contact PI
Multiplex Nucleic Acid Detection Devices for the Diagnosis of Respiratory Viruses$807,359
U01 · FY2010 · AI · contact PI
Orally Active Nucleoside Phosphonates for Hepatitis C Virus$536,480
R01 · FY2010 · AI · contact PI
Research in Infectious Diseases$392,348
T32 · FY2010 · AI · contact PI
International Program$285,669
P30 · FY2010 · AI · contact PI
Orally Active Nucleoside Phosphonates for Hepatitis C Virus$38,872
R01 · FY2010 · AI · contact PI
Multiplex Nucleic Acid Detection Devices for the Diagnosis of Respiratory Viruses$795,295
U01 · FY2009 · AI · contact PI
Orally Active Nucleoside Phosphonates for Hepatitis C Virus$574,983
R01 · FY2009 · AI · contact PI
International Program$287,136
P30 · FY2009 · AI · contact PI
Multiplex Nucleic Acid Detection Devices for the Diagnosis of Respiratory Viruses$775,662
U01 · FY2008 · AI · contact PI
Research in Infectious Diseases$308,515
T32 · FY2008 · AI · contact PI
International Program$179,024
P30 · FY2008 · AI · contact PI
Multiplex Nucleic Acid Detection Devices for the Diagnosis of Respiratory Viruses$824,884
U01 · FY2007 · AI · contact PI
Research in Infectious Diseases$318,476
T32 · FY2007 · AI · contact PI
International Program$236,285
P30 · FY2007 · AI · contact PI
Biochip Diagnostic Tool for BT Induced Diseases$80,183
U54 · FY2007 · AI · contact PI
INTERNATIONAL PROGRAM$347,438
P30 · FY2006 · AI · contact PI
Research in Infectious Diseases$307,991
T32 · FY2006 · AI · contact PI
Biochip Diagnostic Tool for BT Induced Diseases$59,838
U54 · FY2006 · AI · contact PI
Research in Infectious Diseases$317,968
T32 · FY2005 · AI
Biochip Diagnostic Tool for BT Induced Diseases$62,982
U54 · FY2005 · AI
U of Colorado Center for AIDS Research$1,541,289
P30 · FY2004 · AI
The Role of Sex and HCV Co-Infection in HIV Therapy$247,150
P30 · FY2004 · AI
ACTG A5116:2 Regimen Trial for HIV Subjects$44,969
M01 · FY2004 · RR
COLORADO ADULT AIDS CLINICAL TRIALS UNIT$1,903,131
U01 · FY2003 · AI
U of Colorado Center for AIDS Research$1,500,001
P30 · FY2003 · AI
Immunopathogenesis of Acute HIV-1 Infection$1,035,733
P01 · FY2003 · AI
University of Colorado HIV Research Training Program$182,421
T32 · FY2003 · AI
COLORADO ADULT AIDS CLINICAL TRIALS UNIT$1,400,642
U01 · FY2002 · AI
IMMUNOPATHOGENESIS OF ACUTE HIV-1 INFECTION$669,191
U01 · FY2002 · AI
ACTG368 INDINAVIR SULFATE, DMP266 &1592U89 IN HIV INFECTED SUBJECTS$190,747
M01 · FY2002 · RR
3 MAINTENENCE REGIMENS FOR HIV SUBJECTS REC ZIDOVUDINE, LAMIVUDINE, INDINAVIR$190,747
M01 · FY2002 · RR
ACTG 323 FLUCONAZOLE AS THERAPY FOR OROPHARYNGEAL CANDIDIASIS$190,747
M01 · FY2002 · RR
ACTG 362 TRIALS OF AZITHROMYCIN PROPHYLAXIS TO PREVENT MAC DISEASE$190,747
M01 · FY2002 · RR
PHASE II PROLONG VIROLOGIC SUCCESS &OPTN FOR FAILURE IN HIV SUB ON INDINAVIR$190,747
M01 · FY2002 · RR
PHASE II STDY INDINAVIR+NEVIRAPINE+STAVUDINE IN SUBJ PREV TRTD W/ 141W94/VX-478$190,747
M01 · FY2002 · RR
SOFT GELATIN CAPSULE OF SAQUINAVIR IN COMB WI RITONAVIR OR NELFINAVIR$190,747
M01 · FY2002 · RR
PHASE III TRIAL:EFAVIRENZ/ NELFINAVIR IN COMBINATION WI LAMIVUDINE/ZIDOVUDINE$190,747
M01 · FY2002 · RR
ACTG 398, PHASE II TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIB$190,747
M01 · FY2002 · RR
ACTG384 PROTEASE INHIBITOR &/OR NON NUCLEOSIDE REVERSE TRANS INHIBITOR$190,747
M01 · FY2002 · RR
A5025 PHASE II RANDOM STUDY OF HYDROXYUREA IN SUBJ ON POTENT ANTIRETROVIRALS$190,747
M01 · FY2002 · RR
CHEMOTHERAPY/IMMUNOTHERAPY FOR HIV INFECTION$190,747
M01 · FY2002 · RR
DYNAMICS OF HCV INFECTION DURING ANTIRETROVIRAL THERAPY$190,747
M01 · FY2002 · RR
SUBCUTANEOUS IL-2 IN COMBINATION WITH HAART$190,747
M01 · FY2002 · RR
University of Colorado HIV Research Training Program$169,587
T32 · FY2002 · AI
ADULT ACTG CENTRAL GROUP$17,777,099
U01 · FY2001 · AI
COLORADO ADULT AIDS CLINICAL TRIALS UNIT$1,785,928
U01 · FY2001 · AI
IMMUNOPATHOGENESIS OF ACUTE HIV-1 INFECTION$1,051,302
U01 · FY2001 · AI
3 MAINTENENCE REGIMENS FOR HIV SUBJECTS REC ZIDOVUDINE, LAMIVUDINE, INDINAVIR$190,747
M01 · FY2001 · RR
DYNAMICS OF HCV INFECTION DURING ANTIRETROVIRAL THERAPY$190,747
M01 · FY2001 · RR
CHEMOTHERAPY/IMMUNOTHERAPY FOR HIV INFECTION$190,747
M01 · FY2001 · RR
SUBCUTANEOUS IL-2 IN COMBINATION WITH HAART$190,747
M01 · FY2001 · RR
A5025 PHASE II RANDOM STUDY OF HYDROXYUREA IN SUBJ ON POTENT ANTIRETROVIRALS$190,747
M01 · FY2001 · RR
ACTG384 PROTEASE INHIBITOR &/OR NON NUCLEOSIDE REVERSE TRANS INHIBITOR$190,747
M01 · FY2001 · RR
ACTG 398, PHASE II TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIB$190,747
M01 · FY2001 · RR
PHASE III TRIAL:EFAVIRENZ/ NELFINAVIR IN COMBINATION WI LAMIVUDINE/ZIDOVUDINE$190,747
M01 · FY2001 · RR
SOFT GELATIN CAPSULE OF SAQUINAVIR IN COMB WI RITONAVIR OR NELFINAVIR$190,747
M01 · FY2001 · RR
PHASE II STDY INDINAVIR+NEVIRAPINE+STAVUDINE IN SUBJ PREV TRTD W/ 141W94/VX-478$190,747
M01 · FY2001 · RR
PHASE II PROLONG VIROLOGIC SUCCESS &OPTN FOR FAILURE IN HIV SUB ON INDINAVIR$190,747
M01 · FY2001 · RR
ACTG 362 TRIALS OF AZITHROMYCIN PROPHYLAXIS TO PREVENT MAC DISEASE$190,747
M01 · FY2001 · RR
ACTG 323 FLUCONAZOLE AS THERAPY FOR OROPHARYNGEAL CANDIDIASIS$190,747
M01 · FY2001 · RR
ACTG368 INDINAVIR SULFATE, DMP266 &1592U89 IN HIV INFECTED SUBJECTS$190,747
M01 · FY2001 · RR
UNIVERSITY OF COLORADO HIV RESEARCH TRAINING PROGRAM$57,451
T32 · FY2001 · AI
SOFT GELATIN CAPSULE OF SAQUINAVIR IN COMB WI RITONAVIR OR NELFINAVIR$0
M01 · FY2001 · RR
ACTG 323 FLUCONAZOLE AS THERAPY FOR OROPHARYNGEAL CANDIDIASIS$0
M01 · FY2001 · RR
3 MAINTENENCE REGIMENS FOR HIV SUBJECTS REC ZIDOVUDINE, LAMIVUDINE, INDINAVIR$0
M01 · FY2001 · RR
A5025 PHASE II RANDOM STUDY OF HYDROXYUREA IN SUBJ ON POTENT ANTIRETROVIRALS$0
M01 · FY2001 · RR
ACTG 362 TRIALS OF AZITHROMYCIN PROPHYLAXIS TO PREVENT MAC DISEASE$0
M01 · FY2001 · RR
PHASE III TRIAL:EFAVIRENZ/ NELFINAVIR IN COMBINATION WI LAMIVUDINE/ZIDOVUDINE$0
M01 · FY2001 · RR
CHEMOTHERAPY/IMMUNOTHERAPY FOR HIV INFECTION$0
M01 · FY2001 · RR
PHASE II STDY INDINAVIR+NEVIRAPINE+STAVUDINE IN SUBJ PREV TRTD W/ 141W94/VX-478$0
M01 · FY2001 · RR
SUBCUTANEOUS IL-2 IN COMBINATION WITH HAART$0
M01 · FY2001 · RR
DYNAMICS OF HCV INFECTION DURING ANTIRETROVIRAL THERAPY$0
M01 · FY2001 · RR
PHASE II PROLONG VIROLOGIC SUCCESS &OPTN FOR FAILURE IN HIV SUB ON INDINAVIR$0
M01 · FY2001 · RR
ACTG368 INDINAVIR SULFATE, DMP266 &1592U89 IN HIV INFECTED SUBJECTS$0
M01 · FY2001 · RR
ACTG384 PROTEASE INHIBITOR &/OR NON NUCLEOSIDE REVERSE TRANS INHIBITOR$0
M01 · FY2001 · RR
ACTG 398, PHASE II TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIB$0
M01 · FY2001 · RR
ADULT ACTG CENTRAL GROUP$17,606,010
U01 · FY2000 · AI
COLORADO ADULT AIDS CLINICAL TRIALS UNIT$1,834,346
U01 · FY2000 · AI
IMMUNOPATHOGENESIS OF ACUTE HIV-1 INFECTION$1,209,516
U01 · FY2000 · AI
UNIVERSITY OF COLORADO HIV RESEARCH TRAINING PROGRAM$104,879
T32 · FY2000 · AI
INFLUENCE OF RISK STATUS FOR DISEASE PROGRESSION ON THE RESPONSE TO INTERVENTION$32,212
M01 · FY2000 · RR
ACTG347 PHASE II STUDY OF 141W94/VX478 MONOTHERAPY VS 141W94/VX + ZIDOVUDINE$32,212
M01 · FY2000 · RR
ACTG 315 RITONAVIR, ZIDOVUDINE AND LAMIVUDINE IN ADVANCED HIV 1 DISEASE$32,212
M01 · FY2000 · RR
ACTG 320 PHASE III INDINAVIR SULFATE$32,212
M01 · FY2000 · RR
ACTG 285 STEM CELL MOBILIZATION AND HARVESTING WITH FILGRASTIM$32,212
M01 · FY2000 · RR
VIROLOGIC RESPONSES TO NEW NUCLEOSIDE REGIMENS AFTER ZDV OR DDI MONOTHERAPY$32,212
M01 · FY2000 · RR
ACTG384 PROTEASE INHIBITOR &/OR NON NUCLEOSIDE REVERSE TRANS INHIBITOR$32,212
M01 · FY2000 · RR
ACTG 398, PHASE II TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIB$32,212
M01 · FY2000 · RR
PHASE III TRIAL:EFAVIRENZ/ NELFINAVIR IN COMBINATION WI LAMIVUDINE/ZIDOVUDINE$32,212
M01 · FY2000 · RR
SOFT GELATIN CAPSULE OF SAQUINAVIR IN COMB WI RITONAVIR OR NELFINAVIR$32,212
M01 · FY2000 · RR
PHASE II STDY INDINAVIR+NEVIRAPINE+STAVUDINE IN SUBJ PREV TRTD W/ 141W94/VX-478$32,212
M01 · FY2000 · RR
PHASE II PROLONG VIROLOGIC SUCCESS &OPTN FOR FAILURE IN HIV SUB ON INDINAVIR$32,212
M01 · FY2000 · RR
ACTG 362 TRIALS OF AZITHROMYCIN PROPHYLAXIS TO PREVENT MAC DISEASE$32,212
M01 · FY2000 · RR
ACTG 323 FLUCONAZOLE AS THERAPY FOR OROPHARYNGEAL CANDIDIASIS$32,212
M01 · FY2000 · RR
ACTG368 INDINAVIR SULFATE, DMP266 &1592U89 IN HIV INFECTED SUBJECTS$32,212
M01 · FY2000 · RR
3 MAINTENENCE REGIMENS FOR HIV SUBJECTS REC ZIDOVUDINE, LAMIVUDINE, INDINAVIR$32,212
M01 · FY2000 · RR
VIROLOGIC RESPONSES TO NEW NUCLEOSIDE REGIMENS AFTER ZDV OR DDI MONOTHERAPY$0
M01 · FY2000 · RR
ACTG 285 STEM CELL MOBILIZATION AND HARVESTING WITH FILGRASTIM$0
M01 · FY2000 · RR
PHASE II STDY INDINAVIR+NEVIRAPINE+STAVUDINE IN SUBJ PREV TRTD W/ 141W94/VX-478$0
M01 · FY2000 · RR
PHASE II PROLONG VIROLOGIC SUCCESS &OPTN FOR FAILURE IN HIV SUB ON INDINAVIR$0
M01 · FY2000 · RR
ACTG 320 PHASE III INDINAVIR SULFATE$0
M01 · FY2000 · RR
ACTG 362 TRIALS OF AZITHROMYCIN PROPHYLAXIS TO PREVENT MAC DISEASE$0
M01 · FY2000 · RR
ACTG 315 RITONAVIR, ZIDOVUDINE AND LAMIVUDINE IN ADVANCED HIV 1 DISEASE$0
M01 · FY2000 · RR
ACTG 323 FLUCONAZOLE AS THERAPY FOR OROPHARYNGEAL CANDIDIASIS$0
M01 · FY2000 · RR
ACTG347 PHASE II STUDY OF 141W94/VX478 MONOTHERAPY VS 141W94/VX + ZIDOVUDINE$0
M01 · FY2000 · RR
ACTG368 INDINAVIR SULFATE, DMP266 &1592U89 IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
3 MAINTENENCE REGIMENS FOR HIV SUBJECTS REC ZIDOVUDINE, LAMIVUDINE, INDINAVIR$0
M01 · FY2000 · RR
CHEMOTHERAPY/IMMUNOTHERAPY FOR HIV INFECTION$0
M01 · FY2000 · RR
DYNAMICS OF HCV INFECTION DURING ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
DYNAMICS OF HCV INFECTION DURING ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
CHEMOTHERAPY/IMMUNOTHERAPY FOR HIV INFECTION$0
M01 · FY2000 · RR
A5025 PHASE II RANDOM STUDY OF HYDROXYUREA IN SUBJ ON POTENT ANTIRETROVIRALS$0
M01 · FY2000 · RR
A5025 PHASE II RANDOM STUDY OF HYDROXYUREA IN SUBJ ON POTENT ANTIRETROVIRALS$0
M01 · FY2000 · RR
ACTG384 PROTEASE INHIBITOR &/OR NON NUCLEOSIDE REVERSE TRANS INHIBITOR$0
M01 · FY2000 · RR
SUBCUTANEOUS IL-2 IN COMBINATION WITH HAART$0
M01 · FY2000 · RR
SUBCUTANEOUS IL-2 IN COMBINATION WITH HAART$0
M01 · FY2000 · RR
ACTG 398, PHASE II TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIB$0
M01 · FY2000 · RR
INFLUENCE OF RISK STATUS FOR DISEASE PROGRESSION ON THE RESPONSE TO INTERVENTION$0
M01 · FY2000 · RR
PHASE III TRIAL:EFAVIRENZ/ NELFINAVIR IN COMBINATION WI LAMIVUDINE/ZIDOVUDINE$0
M01 · FY2000 · RR
SOFT GELATIN CAPSULE OF SAQUINAVIR IN COMB WI RITONAVIR OR NELFINAVIR$0
M01 · FY2000 · RR